These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9327897)

  • 41. [Catechol-o-methyltransferase, monoamino-oxidase and the inactivation of exogenous catecholamines].
    Barac G
    Arch Int Physiol Biochim; 1967 Apr; 75(2):356-7. PubMed ID: 4166464
    [No Abstract]   [Full Text] [Related]  

  • 42. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R; Lecht S; Lazarovici P
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lymphocytic choriomeningitis virus-induced modification of catecholamine metabolism in developing rat brain.
    Guchhait RB; Monjan AA
    Neuroscience; 1980; 5(6):1105-11. PubMed ID: 7402458
    [No Abstract]   [Full Text] [Related]  

  • 44. Rudolf Buchheim lecture. The metabolizing systems involved in the inactivation of catecholamines.
    Trendelenburg U
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):201-7. PubMed ID: 3713866
    [No Abstract]   [Full Text] [Related]  

  • 45. Characterization of enzymes of catecholamine synthesis and metabolism in human fetal membranes at birth.
    Casimiri V; Acker G; Parvez S; Parvez H; Castro L; Hobel C; Papiernik E
    Am J Obstet Gynecol; 1991 Feb; 164(2):599-603. PubMed ID: 1992709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Monoamine oxidase and essential arterial hypertension].
    Sicuteri F; Del Bene E; Anselmi B; Del Bianco PL
    Boll Soc Ital Biol Sper; 1967 Sep; 43(17):1055-8. PubMed ID: 6077438
    [No Abstract]   [Full Text] [Related]  

  • 48. Neuropharmacology of the affective disorders.
    Schildkraut JJ
    Annu Rev Pharmacol; 1973; 13():427-54. PubMed ID: 4197470
    [No Abstract]   [Full Text] [Related]  

  • 49. [Certain neurochemical aspects of the metabolism of hormones and mediators (development of a single concept].
    Utevskiĭ AM; Osinskaia VO
    Vopr Biokhim Mozga; 1978; 13():260-6. PubMed ID: 41365
    [No Abstract]   [Full Text] [Related]  

  • 50. [Modification of catecholamine metabolism in rats by magnesium aspartate hydrochloride].
    Kietzmann M; Kreisner M
    Dtsch Tierarztl Wochenschr; 1990 Apr; 97(4):177-80. PubMed ID: 2351057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Understanding biochemical pathology of depressive illness. An overview.
    Jain M; Jain KM
    Psychiatr Neurol Neurochir; 1973; 76(4):285-95. PubMed ID: 4354410
    [No Abstract]   [Full Text] [Related]  

  • 52. The therapeutic potential of monoamine oxidase inhibitors.
    Youdim MB; Edmondson D; Tipton KF
    Nat Rev Neurosci; 2006 Apr; 7(4):295-309. PubMed ID: 16552415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Role of catechol methyltransferase in catecholamine metabolism in the rat hypothalamus in the remote period after irradiation].
    Prokudina EA; Bazanova NV
    Radiobiologiia; 1982; 22(5):672-4. PubMed ID: 7178440
    [No Abstract]   [Full Text] [Related]  

  • 55. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of amitriptyline on the activity of enzymes participating in biogenic amine metabolism in patients with affective disorders].
    Matsumoto H; Pietruszewska I; Marcjan K
    Psychiatr Pol; 1983; 17(5-6):417-20. PubMed ID: 6669662
    [No Abstract]   [Full Text] [Related]  

  • 57. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of O-methylated catecholamine levels in plasma and urine for diagnosis of autonomic disorders.
    Oeltmann T; Carson R; Shannon JR; Ketch T; Robertson D
    Auton Neurosci; 2004 Nov; 116(1-2):1-10. PubMed ID: 15556832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urinary catecholamines and their metabolites in kwashiorkor.
    Kader MM; Aziz MT; Kamel HB; Fayad I; Rashed MM
    Acta Biol Med Ger; 1974; 33(2):223-9. PubMed ID: 4463638
    [No Abstract]   [Full Text] [Related]  

  • 60. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.